image of Laura Quill
  • Telehealth Visits
bch logo

Laura Quill, CPNP

Hematology and Medical Oncology • Medical Oncology
Pediatric Hematology Mission Bay
877-822-4453
image of Laura Quill
image of Laura Quill
bch logo

Laura Quill, CPNP

Hematology and Medical Oncology • Medical Oncology
Pediatric Hematology Mission Bay
877-822-4453
  • Telehealth Visits

On this page

About me

Laura Quill is a pediatric nurse practitioner who specializes in caring for children with blood disorders, including sickle cell anemia and thalassemia. As a member of a comprehensive care team, she provides physical examinations and assessments, helps coordinate treatments, and assists with patient education and follow-up visits.

Quill earned her bachelor's degree in nursing at Boston College and a master's degree at Columbia University, training in the pediatric primary care nursing program.

Quill gives educational lectures and helps train new nursing staff, and is a mentor in the UCSF Master's Entry Program in Nursing.

Education

Board Certification

  • Child and Adolescent Behavioral Health in Hospital and Specialty Settings, Pediatric Nursing Certification Board (PNCB)
  • Pediatric Nurse Practitioner, Pediatric Nursing Certification Board (PNCB)

School

  • MSN, Columbia University College of Physicians and Surgeons
  • BSN, Boston College

Care Keywords

  • Services
    • Hematology and Medical Oncology
    • Medical Oncology
    • Pediatric Hematology-Oncology

Locations

    Provider Research Listing

    Browse clinical trials and publications by this provider

    Please check with your health insurance plan regarding coverage for this type of care. Not all providers at UCSF Health are covered by every insurance plan.

    For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here.

    The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.